Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
Efficacy of subcutaneous once-weekly semaglutide in recently diagnosed
type 2 diabetes participants: An individual-level, pooled analysis of
SUSTAIN trials
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.